The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab

Myung S. Kim; Vinay Prasad

doi:10.1001/jamainternmed.2019.4694

The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab

Myung S. Kim, Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	315-317
Number of pages	3
Journal	JAMA internal medicine
Volume	180
Issue number	2
DOIs	https://doi.org/10.1001/jamainternmed.2019.4694
State	Published - Feb 2020

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1001/jamainternmed.2019.4694

Cite this

@article{c7ed28a4e8b14ab7bf65d8b8a3edd3c3,

title = "The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab",

author = "Kim, {Myung S.} and Vinay Prasad",

note = "Funding Information: National Institutes of Health (NIH) policy requires that nonapplicable clinical trials (non-ACTs) funded by grants submitted to NIH from January 18, 2017, also submit results.2 Funding Information: Author Contributions: Dr Kim had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Prasad. Acquisition, analysis, or interpretation of data: Kim. Drafting of the manuscript: Kim. Critical revision of the manuscript for important intellectual content: Prasad. Supervision: Prasad. Conflict of Interest Disclosures: Dr Prasad receives research funding from the Laura and John Arnold Foundation. He also reports receiving royalties from his book Ending Medical Reversal; that his work is funded by the Laura and John Arnold Foundation; and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies and payments for contributions to Medscape. Dr Prasad also hosts the podcast Plenary Session, which has Patreon backers. No other disclosures were reported. 1. Gulbis B, Eleftheriou A, Angastiniotis M, et al. Epidemiology of rare anaemias in Europe. Adv Exp Med Biol. 2010;686:375-396. doi:10.1007/978-90-481-9485-8_22 2. Herper M. The world's most expensive drugs. https://www.forbes.com/2010/ 02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html. Published 2010. Accessed June 25, 2019.",

year = "2020",

month = feb,

doi = "10.1001/jamainternmed.2019.4694",

language = "English (US)",

volume = "180",

pages = "315--317",

journal = "JAMA internal medicine",

issn = "2168-6106",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab

AU - Kim, Myung S.

AU - Prasad, Vinay

N1 - Funding Information: National Institutes of Health (NIH) policy requires that nonapplicable clinical trials (non-ACTs) funded by grants submitted to NIH from January 18, 2017, also submit results.2 Funding Information: Author Contributions: Dr Kim had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Prasad. Acquisition, analysis, or interpretation of data: Kim. Drafting of the manuscript: Kim. Critical revision of the manuscript for important intellectual content: Prasad. Supervision: Prasad. Conflict of Interest Disclosures: Dr Prasad receives research funding from the Laura and John Arnold Foundation. He also reports receiving royalties from his book Ending Medical Reversal; that his work is funded by the Laura and John Arnold Foundation; and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies and payments for contributions to Medscape. Dr Prasad also hosts the podcast Plenary Session, which has Patreon backers. No other disclosures were reported. 1. Gulbis B, Eleftheriou A, Angastiniotis M, et al. Epidemiology of rare anaemias in Europe. Adv Exp Med Biol. 2010;686:375-396. doi:10.1007/978-90-481-9485-8_22 2. Herper M. The world's most expensive drugs. https://www.forbes.com/2010/ 02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html. Published 2010. Accessed June 25, 2019.

PY - 2020/2

Y1 - 2020/2

UR - http://www.scopus.com/inward/record.url?scp=85074257663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074257663&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2019.4694

DO - 10.1001/jamainternmed.2019.4694

M3 - Letter

C2 - 31657842

AN - SCOPUS:85074257663

SN - 2168-6106

VL - 180

SP - 315

EP - 317

JO - JAMA internal medicine

JF - JAMA internal medicine

IS - 2

ER -

The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this